Abstract
Oxidative stress due to imbalance between ROS production and detoxification plays a pivotal role in determining cell fate. In response to the excessive ROS, apoptotic signaling pathway is activated to promote normal cell death. However, through deregulation of biomolecules, high amount of ROS promotes carcinogenesis in cells with defective signaling factors. In this line, NRF2 appears to be as a master regulator, which protects cells from oxidative and electrophilic stress. Nrf2 is an intracellular transcription factor that regulates the expression of a number of genes to encode anti-oxidative enzymes, detoxifying factors, anti-apoptotic proteins and drug transporters. Under normal condition, Nrf2 is commonly degraded in cytoplasm by interaction with Keap1 inhibitor as an adaptor for ubiquitination factors. However, high amount of ROS activates tyrosine kinases to dissociate Nrf2: Keap1 complex, nuclear import of Nrf2 and coordinated activation of cytoprotective gene expression. Nevertheless, deregulation of Nrf2 and/or Keap1 due to mutation and activated upstream oncogenes is associated with nuclear accumulation and constitutive activation of Nrf2 to protect cells from apoptosis and induce proliferation, metastasis and chemoresistance. Owning to the interplay of ROS and Nrf2 signaling pathways with carcinogenesis, Nrf2 modulation seems to be important in the personalization of cancer therapy.
Keywords: Antioxidant, Cancer, Keap1, Nrf2, ROS, Oxidative stress.
Current Cancer Drug Targets
Title:Oxidative Stress and Cancer: The Role of Nrf2
Volume: 18 Issue: 6
Author(s): Soraya Sajadimajd and Mozafar Khazaei*
Affiliation:
- Fertility and Infertility Research Center, Kermanshah University of Medical Sciences, Kermanshah,Iran
Keywords: Antioxidant, Cancer, Keap1, Nrf2, ROS, Oxidative stress.
Abstract: Oxidative stress due to imbalance between ROS production and detoxification plays a pivotal role in determining cell fate. In response to the excessive ROS, apoptotic signaling pathway is activated to promote normal cell death. However, through deregulation of biomolecules, high amount of ROS promotes carcinogenesis in cells with defective signaling factors. In this line, NRF2 appears to be as a master regulator, which protects cells from oxidative and electrophilic stress. Nrf2 is an intracellular transcription factor that regulates the expression of a number of genes to encode anti-oxidative enzymes, detoxifying factors, anti-apoptotic proteins and drug transporters. Under normal condition, Nrf2 is commonly degraded in cytoplasm by interaction with Keap1 inhibitor as an adaptor for ubiquitination factors. However, high amount of ROS activates tyrosine kinases to dissociate Nrf2: Keap1 complex, nuclear import of Nrf2 and coordinated activation of cytoprotective gene expression. Nevertheless, deregulation of Nrf2 and/or Keap1 due to mutation and activated upstream oncogenes is associated with nuclear accumulation and constitutive activation of Nrf2 to protect cells from apoptosis and induce proliferation, metastasis and chemoresistance. Owning to the interplay of ROS and Nrf2 signaling pathways with carcinogenesis, Nrf2 modulation seems to be important in the personalization of cancer therapy.
Export Options
About this article
Cite this article as:
Sajadimajd Soraya and Khazaei Mozafar *, Oxidative Stress and Cancer: The Role of Nrf2, Current Cancer Drug Targets 2018; 18 (6) . https://dx.doi.org/10.2174/1568009617666171002144228
DOI https://dx.doi.org/10.2174/1568009617666171002144228 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oncologic Imaging End-Points for the Assessment of Therapy Response
Recent Patents on Anti-Cancer Drug Discovery MicroRNA-203: Tumor Suppression and Beyond
MicroRNA New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) Applications of Nanosystems to Anticancer Drug Therapy (Part I. Nanogels, Nanospheres, Nanocapsules)
Recent Patents on Anti-Cancer Drug Discovery Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry Review of 5-HT4R Ligands: State of Art and Clinical Applications
Current Topics in Medicinal Chemistry Application of Genetic Polymorphisms in DNA Repair in the Prediction of Cancer Susceptibility and Clinical Outcome
Current Pharmacogenomics An Overview of Nano Delivery Systems for Targeting RNA Interference-based Therapy in Ulcerative Colitis
Current Pharmaceutical Design Genomic Sequence Analysis of EGFR Regulation by MicroRNAs in Lung Cancer
Current Topics in Medicinal Chemistry Phage Display Applications for Molecular Imaging
Current Pharmaceutical Biotechnology Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies
Current Nanoscience Importance of Dietary Supplements to the Health
Current Nutrition & Food Science Minimally Invasive Approach to Endometrial Cancer: Robotics and Laparoscopy
Current Women`s Health Reviews Evolution of Ipsilateral Head and Neck Radiotherapy
Current Cancer Therapy Reviews Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Is there U-turn from Insulin Back to Pills in Diabetes?
Current Vascular Pharmacology Current Innovations in Laparoscopy
Current Women`s Health Reviews Genetic and Epigenetic Regulation of Phosphoinositide 3-kinase Isoforms
Current Pharmaceutical Design Involvement of Cysteine Proteases in Cancer
Current Medicinal Chemistry